Linezolid (Zyvox) and Ketamine Therapy | Tovani Health
Zyvox (Linezolid) — Oxazolidinone antibiotic (reversible MAO inhibitor)
Verdict at Tovani Health
Not currently a candidate for at-home KAP while on active linezolid therapy. Eligible after the course finishes and a washout period.
Patients on active linezolid are not candidates for at-home ketamine therapy at Tovani Health. This is an operational position, not an evidentiary claim that the combination is universally dangerous. The published case literature is thinner than older safety language suggests; the Veraart 2021 and 2022 work on ketamine plus MAO inhibitors found no documented hypertensive crisis or serotonin syndrome in monitored clinical settings, and the FDA's linezolid warning specifically concerns serotonergic agents like SSRIs and SNRIs rather than ketamine. The reason we hold is mechanism plus setting: ketamine raises BP via indirect catecholamine release, linezolid reversibly inhibits MAO and slows catecholamine clearance, and at-home unmonitored sessions are not the place to test how that interaction will go for a given patient. After your linezolid course is finished and a conservative 14-day washout has passed under your prescriber's care, you become eligible.
If you take Zyvox regularly and are considering at-home ketamine therapy, the combination is not currently a candidate. This page covers the brief pharmacologic context and what we do at intake.
How Zyvox interacts with ketamine
Linezolid reversibly inhibits MAO-A and MAO-B as a side effect of its antibacterial activity. Ketamine acutely raises BP and HR by indirectly increasing catecholamine activity (norepinephrine reuptake inhibition, central sympathetic outflow). With MAO partially inhibited, the released catecholamines clear more slowly, theoretically raising the risk of a hypertensive episode. Same operational reasoning the anesthesia literature applies to scheduled procedures on MAOI patients: combination is doable in a monitored environment, not appropriate unmonitored.
What we do at intake
Disclose current or recent linezolid use. We do not run sessions during active therapy. After completing the course, a 14-day washout puts you back in the eligibility window. If you have an active resistant Gram-positive infection requiring linezolid, that treatment takes priority and KAP waits.
Bottom line
Patients on active linezolid are not candidates for at-home ketamine therapy at Tovani Health. This is an operational position, not an evidentiary claim that the combination is universally dangerous. The published case literature is thinner than older safety language suggests; the Veraart 2021 and 2022 work on ketamine plus MAO inhibitors found no documented hypertensive crisis or serotonin syndrome in monitored clinical settings, and the FDA's linezolid warning specifically concerns serotonergic agents like SSRIs and SNRIs rather than ketamine. The reason we hold is mechanism plus setting: ketamine raises BP via indirect catecholamine release, linezolid reversibly inhibits MAO and slows catecholamine clearance, and at-home unmonitored sessions are not the place to test how that interaction will go for a given patient. After your linezolid course is finished and a conservative 14-day washout has passed under your prescriber's care, you become eligible.
Frequently Asked Questions
I am finishing a course of Zyvox in two days. When can I start KAP?
Two weeks after the last dose. The serotonergic effect persists past the active dosing window.
What would change this answer
We don’t prescribe at-home ketamine in this scenario today, but the situation can change. Talk to your prescribing physician about whether the underlying clinical picture (medication change, dose taper, indication shift, or stabilization milestone) might make you eligible later. We’re happy to revisit if your circumstances change.
For immediate mental health support, the 988 Suicide & Crisis Lifeline is available 24/7 (call or text 988).
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression. Veraart JKE, Smith-Apeldoorn SY, et al.. Journal of Clinical Psychiatry. 2022. PMID: 36300995
Prospective N=39 series of ketamine in patients on antidepressants including MAOIs; no adverse events reported with appropriate monitoring.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression. Veraart JKE, Smith-Apeldoorn SY, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Systematic review of ketamine interactions with psychiatric medications including MAO inhibitors; no documented serotonin syndrome or hypertensive crisis in supervised use.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.